ZTS Zoetis (ZTS) Q4 FY24 earnings call
Zoetis delivered robust Q4 and full-year 2024 results, driven by strong performance in its Companion Animal portfolio, particularly the Simparica franchise and OA Pain mAbs. The company's diversified business model and strategic investments in innovation are expected to sustain above-market growth, despite anticipated competitive entries and foreign exchange headwinds in 2025.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ZTS operating KPIs by quarter
| KPI | This call Dec 2024 Q4 FY24 | Jun 2025 Q2 FY25 | Change vs prior quarter |
|---|---|---|---|
| Patients Librela | 1.2M+Librela, now entering its second year in the market, generated $53 million, growing 21% on the quarter and reaching more than 1.2 million patients.Source: earnings call transcript | 1MAnd today, we are reaching just 1 million of them.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.